Institutional investors hold a majority ownership of BIIB through the 91.25% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended March 2017, these large investors purchased a net $747.6 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
JANUS CAPITAL MANAGEMENT LLC Bought 1.3 Million shares of Biogen
MASSACHUSETTS FINANCIAL SERVICES... Bought 1.3 Million shares of Biogen
WINSLOW CAPITAL MANAGEMENT LLC Bought 1.3 Million shares of Biogen